Pharmacoeconomic analysis of schemes of pharmacotherapy of irritable bowel syndrome using the method of "minimization of costs"




irritable bowel syndrome, antispasmodics, «cost minimization» method, pharmacotherapy


Irritable bowel syndrome (IBS) is a clinical pathology, accompanied by significant physical and psychological discomfort, and leading to certain economic losses. Women suffer from IBS 2.2 times more often than men.

The purpose of the study is to conduct a comparative analysis of recommended drugs for treating patients with IBS by minimizing costs and choosing treatment regimens that allow you to save money with the same efficacy of therapy.

Materials and methods. The cost minimization analysis (CMA) of drugs are using data on the cost of drugs for 2018. The course of primary pharmacotherapy was calculated on a combination of antispasmodic and Loperamide, lasting 4 weeks (28 days).

Results and its discussion. For the treatment of IBS is important combination of diet, pharmacotherapy and psychotherapy. Therefore, the calculation was maden for the treatment of IBS with a predominance of diarrhea of two drugs - antispasmodic and Loperamide.

After analyzing the cost of treatment regimens, we can note that the cheapest regimen with INN Mebeverin was the regimen with drugs ASPASMIN and LOPERAMIDE HYDROCHLORIDE. The total cost of the scheme was UAH 287.94.

Otilonium bromide is represented by only one TN, and the final price of the treatment regimen with this drug depends on Loperamide. The treatment regimen with LOPERAMIDE HYDROCHLORIDE of Ukrainian production (UAH 320.65 per course) turned out to be cheaper.

The cheapest treatment regimen with Drotaverin was the one with two drugs of domestic production - NO-KH-SHA® and LOPERAMIDE HYDROCHLORIDE (141.01 UAH).

Conclution. It has been established that the difference in costs for different treatment schemes depends on the price of drugs, and also on whether it is generic or original (brand), imported or domestic. Most domestic drugs are generic, so treatment regimens will be cheaper and will help save money.


Author Biographies

D. V. Zakorko, National University of Pharmacy

student of the National University of Pharmacy

T. O. Bahlai, National University of Pharmacy

post-graduate student of the Department of Pharmacoeconomy


Lacy, B. E., Mearin, F., Chang, L., Chey, W. D., Lembo, A. J., Simren, M., & Spiller, R. (2016). Bowel Disorders. Gastroenterology, 150(6), 1393–1407.

Card, T., Canavan, C., & West, J. (2014). The epidemiology of irritable bowel syndrome. Clinical Epidemiology, 71.

Klem, F., Wadhwa, A., Prokop, L. J., Sundt, W. J., Farrugia, G., Camilleri, M., … Grover, M. (2017). Prevalence, Risk Factors, and Outcomes of Irritable Bowel Syndrome After Infectious Enteritis: A Systematic Review and Meta-analysis. Gastroenterology, 152(5), 1042–1054.

Serhiienko, Ye. I. (2009). Novyny medytsyny i farmatsii. Hastroenterolohiia, 294. Available at :

Derzhavnyi formuliar likarskych zasobiv, 10. Kyiv, 2018 Available at:

Maidannyk, V. H. (2016). Mizhnarodnyi zhurnal pediatrii, akusherstva ta hinekolohii, 10(1), 8–18.

National Institute for Health and Clinical Excellence. (2008). Irritable bowel syndrome in adults. Diagnosis and management of irritable bowel syndrome in primary care London: NICE. Available at:

Song, K. H., Jung, H.-K., Kim, H. J., Koo, H. S., Kwon, Y. H., … Shin, H. D. (2018). Clinical Practice Guidelines for Irritable Bowel Syndrome in Korea, 2017 Revised Edition. Journal of Neurogastroenterology and Motility, 24(2), 197–215.

Nakaz MOZ Ukrainy Pro zatverdzhennia protokoliv nadannia medychnoi dopomohy za spetsialnistiu "Hastroenterolohiia" zi zminamy № 271 vid 13.06.2005 r. (2005). Available at: